Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation

J Clin Endocrinol Metab. 2017 Jun 1;102(6):2111. doi: 10.1210/jc.2016-4037.

Authors

Sudhaker D Rao¹, Shijing Qiu¹, Ruban Dhaliwal², Sanjay Kumar Bhadada³

Affiliations

¹ Bone and Mineral Research Laboratory, Henry Ford Hospital, Detroit, Michigan 48202.
² Department of Endocrinology, Diabetes and Metabolism, State University of New York Upstate Medical University, Syracuse, New York 13210.
³ Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

PMID: 28586451
DOI: 10.1210/jc.2016-4037

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents
Denosumab*
Humans
Osteoporosis, Postmenopausal
Osteoporotic Fractures
Spinal Fractures*

Substances

Bone Density Conservation Agents
Denosumab